biostudies-literatureHays AGNCATS NIH HHSNIAID NIH HHSNHLBI NIH HHSNCI NIH HHSNIH HHS1041-1050https://www.ebi.ac.uk/biostudies/studies/S-EPMC8916096biostudies-literatureUnknown35(7)<h4>Objectives</h4>People living with HIV (PWH) experience an increased burden of coronary artery disease (CAD) believed to be related, in part, to an interplay of chronically increased inflammation and traditional risk factors. Recent trials suggest cardiovascular benefits of the anti-inflammatory, colchicine, in HIV-seronegative CAD patients. However, the impact of colchicine on impaired vascular health, as measured by coronary endothelial function (CEF), an independent contributor to CAD, has not been studied in PWH. We tested the hypothesis that colchicine improves vascular health in PWH.<h4>Design</h4>This was a randomized, placebo-controlled, double-blinded trial in 81 PWH to test whether low-dose colchicine (0.6 mg daily) improves CEF over 8-24 weeks.<h4>Methods</h4>Coronary and sysAIDS (London, England)A randomized, placebo-controlled, double-blinded clinical trial of colchicine to improve vascular health in people living with HIV.PMC8916096P30 CA006973R56 HL125059UL1 TR003098U01 HL146201K23 HL133358R01 HL147660S10 OD020091R01 HL125059P30 AI094189Kelly SAfework YStradley SMargolick JBBarditch-Crovo PMeyer JSchar MBonanno GWeiss RGAnders NMHays AGLai SStreeb VGerstenblith GBagchi SfalseA randomized, placebo-controlled, double-blinded clinical trial of colchicine to improve vascular health in people living with HIV.<h4>Objectives</h4>People living with HIV (PWH) experience an increased burden of coronary artery disease (CAD) believed to be related, in part, to an interplay of chronically increased inflammation and traditional risk factors. Recent trials suggest cardiovascular benefits of the anti-inflammatory, colchicine, in HIV-seronegative CAD patients. However, the impact of colchicine on impaired vascular health, as measured by coronary endothelial function (CEF), an independent contributor to CAD, has not been studied in PWH. We tested the hypothesis that colchicine improves vascular health in PWH.<h4>Design</h4>This was a randomized, placebo-controlled, double-blinded trial in 81 PWH to test whether low-dose colchicine (0.6 mg daily) improves CEF over 8-24 weeks.<h4>Methods</h4>Coronary and sys2021-01-01T00:00:00Z2021 Jun2026-05-09T20:14:03.152Z2025-04-04T22:01:52.403ZS-EPMC89160963358744310.1097/QAD.000000000000284510.1097/qad.0000000000002845